These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 27128459)

  • 21. Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination.
    Allen A; Murdoch RD; Bareille P; Burns O; Hughes S; Gupta A; Miller SR
    Clin Pharmacol Drug Dev; 2016 May; 5(3):225-31. PubMed ID: 27163502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
    Yang WH; Martinot JB; Pohunek P; Beier J; Magula D; Cameron R; Owen R; Higgins M
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R; Norris V; Siederer S
    Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.
    Bateman ED; Bleecker ER; Lötvall J; Woodcock A; Forth R; Medley H; Davis AM; Jacques L; Haumann B; Busse WW
    Respir Med; 2012 May; 106(5):642-50. PubMed ID: 22342538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.
    Lee LA; Yang S; Kerwin E; Trivedi R; Edwards LD; Pascoe S
    Respir Med; 2015 Jan; 109(1):54-62. PubMed ID: 25452139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.
    Rosenblut A; Bardin PG; Muller B; Faris MA; Wu WW; Caldwell MF; Fokkens WJ
    Allergy; 2007 Sep; 62(9):1071-7. PubMed ID: 17686110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled corticosteroids in children with persistent asthma: effects on growth.
    Zhang L; Prietsch SO; Ducharme FM
    Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis.
    Gradman J; Caldwell MF; Wolthers OD
    Clin Ther; 2007 Aug; 29(8):1738-47. PubMed ID: 17919555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
    Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate.
    Wardlaw A; Larivee P; Eller J; Cockcroft DW; Ghaly L; Harris AG
    Ann Allergy Asthma Immunol; 2004 Jul; 93(1):49-55. PubMed ID: 15281471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
    Chuchalin AG; Manjra AI; Rozinova NN; Skopková O; Cioppa GD; Till D; Kaiser G; Fashola T; Kottakis J
    J Aerosol Med; 2005; 18(1):63-73. PubMed ID: 15741775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma.
    Berger WE; Milgrom H; Chervinsky P; Noonan M; Weinstein SF; Lutsky BN; Staudinger H
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):672-80. PubMed ID: 17165278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
    O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
    Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
    Wasserman RL; Baker JW; Kim KT; Blake KV; Scott CA; Wu W; Faris MA; Crim C
    Ann Allergy Asthma Immunol; 2006 Jun; 96(6):808-18. PubMed ID: 16802768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.